Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

NCT02078752 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02078752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02078752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
April 9, 2014
Completion date
May 10, 2017
Enrollment
60 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, triple-negative breast cancer